Genmab — Juni 2025

[Solsen]

Yes I agree.

[lahn1]

De 2 nye endpoint kan vel være andet end positive, selvom jeg primært ser dem som det. Lyder plasma kontrol lidt som vi var inden på ved resultaterne af ph2, at en individuel doserings regime (timing) ift Aca koncentrationen i plasma ser ud til at kunne optimere effekten ? Discontinuation rate er vel kun forberedelse på godkendelse vs Docetaxel i 2 L og måske bedre forståelse for AE ift med mulige fremtidige kombinationer. Hvordan læse I andre de nye end points ?

[Solsen]

Acasunlimab has a huge potential. Tahi seems very bullish. But data on limited pts until now. But if they can show high number and long responses in NSCLC in second line it could be big.

[lahn1]

Sorry, jeg fik vist blandet koncentratione af acasunlimab i plasma sammen med t-cell exhaustion.

[E_L]

only Time to Treatment Discontinuation Due to AE is new. (the other was already there, the old 5. ) to me the question is more; why wasn't that there in the first place (logical measure)

[lahn1]

Yes as 4-1BB has a history of poor tolerability, it seems logical to be able to show durable tolerability with zero or low discontinuation rates. Docetaxel having 15-20% discontinuation as SOC in 2L NSCLC.

[E_L]

BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer https://investors.biontech.de/news-releases/news-release-details/biontech-announces-strategic-transaction-acquire-curevac-public

[Solsen]

I belive Genmab still have some shares left i CureVac.

[E_L]

they may have, but for a relatively small value. If I remember correct, they invested $20mn and sold a part of that for +-$60mn (?) . The remainder collapsed in value...

[E_L]

Epcoritamab Improves Outcomes, HRQOL in Patients With Relapsed/Refractory Follicular Lymphoma https://www.ajmc.com/view/epcoritamab-improves-outcomes-hrqol-in-patients-with-relapsed-refractory-follicular-lymphoma EHA 2025

[gentogen]

Thanks EL for the link 15:24 yesterday. Pure KYSO...

[Helge_LarsenPI-redaktør]

Oversigt: Ny udgave af ØU Life Science – Genmab accelererer mod blockbusterstatus med Rina-S efter data
https://proinvestor.com/investornyt/1328695/oversigt-ny-udgave-af-ou-life-science-genmab-accelererer-mod-blockbusterstatus-med-rina-s-efter-data

[Helge_LarsenPI-redaktør]

(Artiklen om Genmab kræver ikke abonnement)

[Budweis]

Ser lovende ud https://ml-eu.globenewswire.com/Resource/Download/0b2cf0bd-906b-4985-b4ad-f7d8b772b972

[Budweis]

Genmab Announces Epcoritamab Investigational Combination Therapy
Demonstrates High Response Rates in Patients with Relapsed or
Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for
Autologous Stem Cell Transplantation (ASCT)

[JKY_VH]

Super og mange tak for den Budweis:-)

[Bulder]

Epco fortsætter sin sejrsgang. Det bliver stort - ad åre.

[E_L]

Lymphoma Hub
@lymphomahub
CONGRESS | #EHA2025 | PRESENTATION
Daniel Kerr,
@TGHCares presents updated results from the epcoritamab + pola-R-CHP cohort of the phase Ib/II EPCORE NHL-5
trial (N = 37). https://x.com/lymphomahub/status/1934185493723263388

[E_L]

"These promising results compare favorably to other regimens in 1L and may provide higher cure rates for patients with 1L DLBCL than SOC", suggesting that further exploration is warranted.

[Helge_LarsenPI-redaktør]

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT) https://proinvestor.com/investornyt/1329270/genmab-announces-epcoritamab-investigational-combination-therapy-demonstrates-high-response-rates-in-patients-with-relapsed-or-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl-eligible-for-autologous-stem-cell-trans